Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-trans retinoic acid in acute myeloid leukemia across subtypes
MetadataShow full item record
This publication is intended for no-profit use. Any other use is discouraged and it will remain under copyright laws of the Ferrata Storti Foundation, Pavia, Italy.
Smitheman, K.N. and Severson, T.M. and Rajapurkar, S.R. and McCabe, M.T. and Karpinich, N. and Foley, J. and Pappalardi, M.B. et al. 2019. Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-trans retinoic acid in acute myeloid leukemia across subtypes. Haematologica. 104 (6): pp. 1156-1167.
© 2019 Ferrata Storti Foundation.
Lysine specific demethylase 1 (LSD1) is a histone modifying enzyme that suppresses gene expression through demethylation of lysine 4 on histone H3. The anti-tumor activity of GSK2879552 and GSK-LSD1, potent, selective irreversible inactivators of LSD1, has previously been described. Inhibition of LSD1 results in a cytostatic growth inhibitory effect in a range of acute myeloid leukemia cell lines. To enhance the therapeutic potential of LSD1 inhibition in this disease setting, a combination of LSD1 inhibition and all-trans retinoic acid was explored. All-trans retinoic acid is currently approved for use in acute promyelocytic leukemia in which it promotes differentiation of abnormal blast cells into normal white blood cells. Combined treatment with all-trans retinoic acid and GSK2879552 results in synergistic effects on cell proliferation, markers of differentiation, and, most importantly, cytotoxicity. Ultimately the combination potential for LSD1 inhibition and ATRA will require validation in acute myeloid leukemia patients, and clinical studies to assess this are currently underway.
Showing items related by title, author, creator and subject.
Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphomaDe Smedt, Renate; Morscio, Julie; Reunes, Lindy; Roels, Juliette; Bardelli, Valentina; Lintermans, Beatrice; Van Loocke, Wouter; Almeida, Afonso; Cheung, Laurence ; Kotecha, Rishi ; Mansour, Marc R; Uyttebroeck, Anne; Vandenberghe, Peter; La Starza, Roberta; Mecucci, Cristina; Lammens, Tim; Van Roy, Nadine; De Moerloose, Barbara; Barata, Joao T; Taghon, Tom; Goossens, Steven; Van Vlierberghe, Pieter (2020)T-cell acute lymphoblastic leukemia (T-ALL) and T-cell acute lymphoblastic lymphoma (T-LBL) are aggressive hematological malignancies that are currently treated with high-dose chemotherapy. Over the last several years, ...
Krivospitskaya, O.; Elmabsout, A.; Sundman, E.; Söderström, L.; Ovchinnikova, O.; Gidlöf, A.; Scherbak, N.; Norata, Giuseppe; Samnegård, A.; Törmä, H.; Abdel-Halim, S.; Jansson, J.; Eriksson, P.; Sirsjö, A.; Olofsson, P. (2012)All-trans retinoic acid, controlled by cytochrome P450, family 26 (CYP26) enzymes, potentially has beneficial effects in atherosclerosis treatment. This study investigates CYP26 subfamily B, polypeptide 1 (CYP26B1) in ...
Cheung, Laurence; Tickner, J.; Hughes, A.; Skut, P.; Howlett, M.; Foley, B.; Oommen, J.; Wells, J.; He, B.; Singh, S.; Chua, G.; Ford, J.; Mullighan, C.; Kotecha, R.; Kees, U. (2018)© 2018 The Author(s) The microenvironments of leukemia and cancer are critical for multiple stages of malignancies, and they are an attractive therapeutic target. While skeletal abnormalities are commonly seen in children ...